Lophius Biosciences Announces Granting of Another Key Patent in the U.S.

19-Nov-2010 - Germany

Lophius Biosciences announced that the USTPO has granted the U.S. Patent US 78293318 entitled “Use of urea-adjuvanted polypeptides for diagnosis, prophylaxis and therapy“.

This patent represents a key building block with respect to Lophius Biosciences T-cell based proprietary UREA technology platform, which has been used by the company already for the development of its diagnostic T-Track® Tx test. This test allows the broad and highly sensitive monitoring of cell-mediated immunity (CMI) in immunosuppressed transplant patients. A corresponding patent has been granted in the E.U already and is nationalized in major markets.

"Following the positive decision by the U.S patent office in early 2010 with respect to patent granting for our proprietary Reverse T-Cell technology, we are very delighted to possess broad patent protection for the UREA technology platform in the most important markets worldwide", said Dr. Michael Lutz, CEO of Lophius Biosciences.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

10+ products
4 whitepaper
10+ brochures